Esperion Therapeutics Inc (NASDAQ:ESPR)
| 0.91 BATS BZX Real-Time Price As of 11:30am ET |  -0.06 / -6.19%Today’s Change | 0.85 Today|||52-Week Range 8.87 | -85.39% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $105.6M |
Company Description
Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Contact Information
Esperion Therapeutics, Inc. 3891 Ranchero Drive Ann Arbor Michigan 48108 |
Employees
Shareholders
| Other institutional | 55.75% |
| Mutual fund holders | 21.24% |
| Individual stakeholders | 14.91% |
Top Executives
| Sheldon L. Koenig | President, Chief Executive Officer & Director |
| Benjamin Halladay | Chief Financial Officer |
| Ken Fiorelli | Chief Technical Operations Officer |
| JoAnne Micale Foody | Chief Medical Officer |
| William J. Sasiela | Senior Vice President-Clinical Development |
